Trial Profile
Selective Endothelin Type A Receptor Inhibition In Cardiac Surgery Subjects With Pre-Existing Cardiovascular Risk Factors: A Dose Confirmation Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Sitaxentan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms FCAD02
- Sponsors Pfizer
- 12 Aug 2022 according to ClinicalTrials.gov record, protocol has been amended as addition of primary endpoint as Percent Change From 0 Hour in Pulmonary Vascular Resistance (PVR) at 0.25h-24 Hour Post-separation From Cardiopulmonary Bypass (CPB) and Number of Participants With Myocardial Infarction, Cerebrovascular Event, Hemodynamic Collapse and Re-operation.
- 18 Dec 2009 New trial record